An interventional study of Hydrus Microstent and Ophthalmic surgery in Open-angle Glaucoma, sponsored by Ivantis, Inc.. Completed at 20 sites in 5 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by Ivantis, Inc. (part of Alcon) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies in Glaucoma, Open-Angle by Alcon — 1 open to participants now, 1 under way, none of them phase 3. Glaucoma, Open-Angle · Alcon.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 42nd largest by enrollment of the 112 interventional ones that give a count, is one of 5 that started in 2017, is one of 10 with no phase, and was the 115th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →1 of the 126 studies in Glaucoma, Open-Angle by Alcon is open now, in 1 country. Recruiting first, the newest first:
Alcon Research · Sites in United States
Ages 45+
By country, each count listing its studies:
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 37 · Phase 3 45 · Phase 4 31
First in 1999; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 217 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 154 across the 112 interventional studies, 88 across the 5 observational. Of the 121 that completed or were terminated, 58 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Ivantis, Inc., one of the names counted as Alcon. Under that name alone:
Ivantis, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent in patients with refractory open-angle glaucoma.
Participants will attend a screening visit, a baseline visit, a surgery visit, and 8 post-operative visits (Day 1, Day 7, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12), for a total individual duration of approximately 14 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hydrus Microstent implanted in the eye per the supplied Hydrus Microstent Instructions for Use and associated training. Only one eye (study eye) will be implanted.
Device: Hydrus Microstent · Procedure: Ophthalmic surgery
Device implanted into the Schlemm's canal of the eye to provide a natural outflow pathway for aqueous humor, leading to a reduction in intraocular pressure (IOP). The Hydrus Microstent is intended for lifetime use of the glaucoma patient.
Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia
Percentage of Subjects With Greater Than or Equal to a 20 Percent Decrease From Baseline in Mean Diurnal Intraocular Pressure (MDIOP) at Month 12 While Maintaining the Same or Fewer Number of Medications as at Baseline
Intraocular pressure was measured using Goldmann Applanation tonometry. Three separate IOP measurements were taken over an 8-hour period and averaged together to achieve mean diurnal intraocular pressure.
Time frame: Baseline, Month 12
Mean Change From Baseline in MDIOP at Month 12
Intraocular pressure was measured using Goldmann Applanation tonometry and recorded in millimeters mercury (mmHG). Three separate IOP measurements were taken over an 8-hour period and averaged together to achieve mean diurnal intraocular pressure. A negative number represents a reduction from baseline. For non-responders, data was imputed as specified in the protocol. No hypothesis testing was pre-specified for this outcome measure.
Time frame: Baseline, Month 12
Participants were recruited from 20 investigative sites located in the United States (16), Philippines (1), Spain (1), United Kingdom (1), and Colombia (1).
| Milestone | Hydrus Microstent |
|---|---|
| Started | 100 |
| Completed | 100 |
| Not completed | 0 |
Intraocular pressure was measured using Goldmann Applanation tonometry. Three separate IOP measurements were taken over an 8-hour period and averaged together to achieve mean diurnal intraocular pressure.
| percentage of subjects | Hydrus Microstent |
|---|---|
| Percentage of Subjects With Greater Than or Equal to a 20 Percent Decrease From Baseline in Mean Diurnal Intraocular Pressure (MDIOP) at Month 12 While Maintaining the Same or Fewer Number of Medications as at Baseline | 43.0 |
Intraocular pressure was measured using Goldmann Applanation tonometry and recorded in millimeters mercury (mmHG). Three separate IOP measurements were taken over an 8-hour period and averaged together to achieve mean diurnal intraocular pressure. A negative number represents a reduction from baseline. For non-responders, data was imputed as specified in the protocol. No hypothesis testing was pre-specified for this outcome measure.
| mmHG | Hydrus Microstent |
|---|---|
| Mean Change From Baseline in MDIOP at Month 12 | -3.77 ± 5.0 |
Collected over Adverse events were collected from the operative visit to study exit (approximately 12 months). AEs were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ocular Adverse Events | 0/100 (0%) | 5/100 (5%) | 55/100 (55%) |
| Non-Ocular Adverse Events | 0/100 (0%) | 0/100 (0%) | 0/100 (0%) |
| Event | Ocular Adverse Events | Non-Ocular Adverse Events |
|---|---|---|
| Worsening of visual fieldEye disorders | 3/100 | 0/100 |
| Elevated mean IOPEye disorders | 2/100 | 0/100 |
| Elevated IOPEye disorders | 1/100 | 0/100 |
| Event | Ocular Adverse Events | Non-Ocular Adverse Events |
|---|---|---|
| Worsening of visual fieldEye disorders | 19/100 | 0/100 |
| Elevated mean IOP at less than or equal to 1 month postoperativeEye disorders | 16/100 | 0/100 |
| BCVA loss at greater than 1 month postoperativeEye disorders | 15/100 | 0/100 |
| Surgical re-intervention in study eyeEye disorders | 15/100 | 0/100 |
| Elevated mean IOP at greater than 1 month postoperativeEye disorders | 14/100 | 0/100 |
| BCVA loss at less than or equal to 1 month postoperativeEye disorders | 10/100 | 0/100 |
| Device obstructionEye disorders | 10/100 | 0/100 |
| Hypotony (less than 6 mmHg)Eye disorders | 7/100 | 0/100 |
| AC cell or flare requiring change in steroid medication regimenEye disorders | 6/100 | 0/100 |
Safety Analysis Population
| Age, Continuous(years) | Hydrus Microstent |
|---|---|
| Mean | 71.3 ± 10.0 |
| Age, Customized(participants) | Hydrus Microstent |
|---|---|
| Less than 60 years | 13 |
| 60 years to less than 70 years | 28 |
| 70 to less than 80 years | 35 |
| 80 years and greater | 24 |
| Sex: Female, Male(Participants) | Hydrus Microstent |
|---|---|
| Female | 52 |
| Male | 48 |
| Race/Ethnicity, Customized(Participants) | Hydrus Microstent |
|---|---|
| Asian | 7 |
| Black or African American | 14 |
| Mestizo | 2 |
| White | 74 |
| Refuses to Answer/Unknown | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2017 to primary completion in Dec 2022, 64 months.
Results were first posted in Jan 2026, 3 years after primary completion. A results delay was requested in Dec 2023.
Of 70 industry-sponsored interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's 64 months is above that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.